View Content
Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?
Since OCM ended in June of 2022, oncology practice leaders have navigated complex decisions about how to offer patients high-quality, value-driven cancer care and in which reimbursement programs they will participate. Program options include true “value-based care” through the new Enhancing Oncology Model, or “value-aligned” programs like Chronic Care Management (CCM) and Principal Care Management (PCM). These programs all have one thing in common: they encourage greater levels of patient support and care coordination. But each has their own set of pros and cons to carefully consider. During this webinar, we will have a lively discussion about the options at hand and review the advantages and considerations for each path a practice could take. Hear from 3 practice leaders about what their path looks like, how they chose it, and how they will navigate it with the help of technology and analytics support.
Submit